This project has been flagged by a community member as inappropriate due to reason below.*

Survey

Slingshot members are conducting a survey! The topic is:

Quarterly Survey: Plaque Psoriasis and Acne Laser Treatments January 2024

Ticker(s): ARQT, DRMT, HOLX, CUTR, BMY

Who's being surveyed?

The survey includes 20 Dermatologists.

Survey Questions
Q1.

How many patients with Plaque Psoriasis do you see on average each month?

Q2.

How many patients seeking Acne laser treatment do you see on average each month?

Q3.

How would you best describe your practice?

  • Community
  • Academic
  • Other

Q4.

How many of your patients with Plaque Psoriasis use the following treatments today:

  • Zoryve (roflumilast):
  • Vtama (tapinarof):
  • Sotyktu (deucravacitinib):

Q5.

How many of your patients do you expect to be using the following treatments in the next 3 months (cumulative)?

  • Zoryve (roflumilast):
  • Vtama (tapinarof):
  • Sotyktu (deucravacitinib):

Q6.

How many of your patients started the following treatments in the last 3 months?

  • Zoryve (roflumilast):
  • Vtama (tapinarof):
  • Sotyktu (deucravacitinib):

Q7.

How many of your patients have discontinued the following treatments in the last 3 months?

  • Zoryve (roflumilast):
  • Vtama (tapinarof):
  • Sotyktu (deucravacitinib):

Q8.

Which of the following topical Plaque Psoriasis treatments do view as the most promising?

  • Zoryve (roflumilast)
  • Vtama (tapinarof)
  • Sotyktu (deucravacitinib)
  • Other
  • None

Q9.

Please elaborate on your view of the Plaque Psoriasis topical treatment that is most promising. Please be specific.

Q10.

How would you rate Zoryve (roflumilast) on the following (where 1 is low and 5 is high)?

  • Safety
  • Efficacy
  • Payor Access

Q11.

How would you rate Vtama (tapinarof) on the following (where 1 is low and 5 is high)?

  • Safety
  • Efficacy
  • Payor Access

Q12.

How would you rate Sotykt (deucravacitinib) on the following (where 1 is low and 5 is high)?

  • Safety
  • Efficacy
  • Payor Access

Q13.

How many of your patients use the following Acne treatments today:

  • Aerolase Laser Treatment:
  • PicoSure Laser Treatment:
  • Lutronic Clarity II:
  • Vbeam Prima Laser Treatment:
  • Isolaz Laser Treatment:
  • Excel V Laser Treatment:
  • AviClear:

Q14.

How many of your patients do you expect to be using the following Acne treatments in the next 3 months (cumulative)?

  • Aerolase Laser Treatment:
  • PicoSure Laser Treatment:
  • Lutronic Clarity II:
  • Vbeam Prima Laser Treatment:
  • Isolaz Laser Treatment:
  • Excel V Laser Treatment:
  • AviClear:

Q15.

How many of your patients started the following Acne treatments in the last 3 months?

  • Aerolase Laser Treatment:
  • PicoSure Laser Treatment:
  • Lutronic Clarity II:
  • Vbeam Prima Laser Treatment:
  • Isolaz Laser Treatment:
  • Excel V Laser Treatment:
  • AviClear:

Q16.

How many of your patients discontinued the following Acne treatments in the last 3 months?

  • Aerolase Laser Treatment:
  • PicoSure Laser Treatment:
  • Lutronic Clarity II:
  • Vbeam Prima Laser Treatment:
  • Isolaz Laser Treatment:
  • Excel V Laser Treatment:
  • AviClear:

Q17.

Which Acne treatment do you view as the most promising?

Q18.

Please elaborate on your view of the most promising Acne treatment above. Please be specific.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.